ARTICLE | Finance

Bug-brain axis

Why Axial is targeting the gut microbiome to treat CNS disorders

December 2, 2016 10:59 PM UTC

Investors supplied Axial Biotherapeutics Inc. with enough cash to get human proof of concept showing that correcting microbiome imbalances can treat pathologies and symptoms of neurological disorders.

The newco debuted Nov. 30 with a $19.2 million series A co-led by Longwood Fund and Domain Associates and joined by Kairos Ventures, Heritage Medical Systems and high net worth individuals...

BCIQ Company Profiles

Axial Therapeutics Inc.